4.29
0.20 (4.89%)
| Previous Close | 4.09 |
| Open | 4.13 |
| Volume | 1,983,486 |
| Avg. Volume (3M) | 1,891,524 |
| Market Cap | 405,182,816 |
| Price / Earnings (Forward) | 54.05 |
| Price / Sales | 0.480 |
| Price / Book | 1.20 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2026 |
| Profit Margin | -12.20% |
| Operating Margin (TTM) | -14.80% |
| Diluted EPS (TTM) | -1.12 |
| Quarterly Revenue Growth (YOY) | -3.10% |
| Total Debt/Equity (MRQ) | 22.36% |
| Current Ratio (MRQ) | 1.90 |
| Operating Cash Flow (TTM) | -6.40 M |
| Levered Free Cash Flow (TTM) | 18.68 M |
| Return on Assets (TTM) | -5.26% |
| Return on Equity (TTM) | -13.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Myriad Genetics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.30 |
|
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 2.77% |
| % Held by Institutions | 104.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Camber Capital Management Lp | 30 Jun 2025 | 2,000,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 6.00 (Wells Fargo, 39.86%) | Hold |
| 6.00 (UBS, 39.86%) | Hold | |
| Median | 6.00 (39.86%) | |
| Average | 6.00 (39.86%) | |
| Total | 2 Hold | |
| Avg. Price @ Call | 4.43 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 24 Feb 2026 | 6.00 (39.86%) | Hold | 4.43 |
| Wells Fargo | 24 Feb 2026 | 6.00 (39.86%) | Hold | 4.43 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DONNELLY BRIAN J | - | 4.80 | -55,975 | -268,680 |
| Aggregate Net Quantity | -55,975 | |||
| Aggregate Net Value ($) | -268,680 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 4.80 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DONNELLY BRIAN J | Officer | 01 May 2026 | Disposed (-) | 55,975 | 4.80 | 268,680 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |